Atheroma and systemic lupus erythematosus

Joint Bone Spine

Volumn 74, Issue 6, 2007, Pages 566-570

  Soubrier, Martin ^a   Mathieu, Sylvain ^a   Dubost, Jean Jacques ^a  

^a SERVICE DE RHUMATOLOGIE   (France)

Author keywords

Atheroma; Cardiovascular disease; Systemic lupus erythematosus

Indexed keywords

ACETYLSALICYLIC ACID; ANTIMALARIAL AGENT; ANTITHROMBOCYTIC AGENT; ANTIVITAMIN K; GLUCOCORTICOID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PHOSPHOLIPID ANTIBODY;

ANTIPHOSPHOLIPID SYNDROME; ARTERY DIAMETER; ARTERY MEDIA; ATHEROMA; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CIGARETTE SMOKING; DYSLIPIDEMIA; HUMAN; HYPERTENSION; INFLAMMATION; INSULIN RESISTANCE; MORBIDITY; MORTALITY; OBESITY; PHYSICAL ACTIVITY; RISK FACTOR; SHORT SURVEY; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANTIMALARIALS; ATHEROSCLEROSIS; CALCINOSIS; CAROTID ARTERIES; CORONARY ARTERY DISEASE; CORONARY VESSELS; GLUCOCORTICOIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LUPUS ERYTHEMATOSUS, SYSTEMIC; RISK FACTORS; TUNICA INTIMA;

EID: 37049016023     PISSN: 1297319X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jbspin.2007.04.006     Document Type: Short Survey

References (54)

1. Urowitz M.B., Bookman A.A., Koehler B.E., Gordon D.A., Smythe H.A., and Ogryzlo M.A. The bimodal mortality pattern of systemic lupus erythematosus. Am J Med 60 (1976) 221-225
2. Bulkley B.H., and Roberts W.C. The heart in systemic lupus erythematosus and the changes induced in it by corticosteroid therapy. A study of 36 necropsy patients. Am J Med 58 (1975) 243-264
3. Manzi S., Meilahn E.N., Rairie J.E., Conte C.G., Medsger Jr. T.A., Jansen-McWilliams L., et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol 145 (1997) 408-415
4. Esdaile J.M., Abrahamowicz M., Grodzicky T., Li Y., Panaritis C., du Berger R., et al. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum 44 (2001) 2331-2337
5. Petri M., Spence D., Bone L.R., and Hochberg M.C. Coronary artery disease risk factors in the Johns Hopkins Lupus Cohort: prevalence, recognition by patients, and preventive practices. Medicine 71 (1992) 291-302
6. Fischer L.M., Schlienger R.G., Matter C., Jick H., and Meier C.R. Effect of rheumatoid arthritis or systemic lupus erythematosus on the risk of first-time acute myocardial infarction. Am J Cardiol 93 (2004) 198-200
7. Bernatsky S., Boivin J.F., Joseph L., Manzi S., Ginzler E., Gladman D.D., et al. Mortality in systemic lupus erythematosus. Arthritis Rheum 54 (2006) 2550-2557
8. Mancini G.B.J., Dahlöf B., and Diez J. Surrogate markers for cardiovascular disease. Structural markers. Circulation 109 Suppl IV (2004) IV-22-IV-38
9. Svenungsson E., Jensen-Urstad K., Heimburger M., Silveira A., Hamsten A., de Faire U., et al. Risk factors for cardiovascular disease in systemic lupus erythematosus. Circulation 104 (2001) 1887-1893
10. Roman M.J., Shanker B.A., Davis A., Lockshin M.D., Sammaritano L., Simantov R., et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med 349 (2003) 2399-2406
11. Asanuma Y., Oeser A., Shintani A.K., Turner E., Olsen N., Fazio S., et al. Premature coronary-artery atherosclerosis in systemic lupus erythematosus. N Engl J Med 349 (2003) 2407-2415
12. Von Feldt J.M., Scalzi L.V., Cucchiara A.J., Morthala S., Kealey C., Flagg S.D., et al. Homocysteine levels and disease duration independently correlate with coronary artery calcification in patients with systemic lupus erythematosus. Arthritis Rheum 54 (2006) 2220-2227
13. Bruce I.N., Urowitz M.B., Gladman D.D., Ibanez D., and Steiner G. Risk factors for coronary heart disease in women with systemic lupus erythematosus: the Toronto Risk Factor Study. Arthritis Rheum 48 (2003) 3159-3167
14. Chung C.P., Oeser A., Avalos I., Raggi P., and Stein C.M. Cardiovascular risk scores and the presence of subclinical coronary artery atherosclerosis in women with systemic lupus erythematosus. Lupus 15 (2006) 562-569
15. Executive summary of the third report of the National Cholesterol Education Program (NCEP). Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult treatment panel III). JAMA 285 (2001) 2486-2497
16. Prise en charge thérapeutique du patient dyslipidémique (2005), AFSSAPS
17. Bruce I.N. 'Not only...but also': factors that contribute to accelerated atherosclerosis and premature coronary heart disease in systemic lupus erythematosus. Rheumatology (Oxford) 44 (2005) 1492-1502
18. Bruce I.N., Urowitz M.B., Gladman D.D., and Hallett D.C. Natural history of hypercholesterolemia in systemic lupus erythematosus. J Rheumatol 26 (1999) 2137-2143
19. Bessant R., Hingorani A., Patel L., MacGregor A., Isenberg D.A., and Rahman A. Risk of coronary heart disease and stroke in a large British cohort of patients with systemic lupus erythematosus. Rheumatology 43 (2004) 924-929
20. Selzer F., Sutton-Tyrrell K., Fitzgerald S.G., Pratt J.E., Tracy R.P., Kuller L.H., et al. Comparison of risk factors for vascular disease in the carotid artery and aorta in women with systemic lupus erythematosus. Arthritis Rheum 50 (2004) 151-159
21. Ohlenschlaeger T., Garred P., Madsen H.O., and Jacobsen S. Mannose-binding lectin variant alleles and the risk of arterial thrombosis in systemic lupus erythematosus. N Engl J Med 15 351 (2004) 260-267
22. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 340 (1999) 115-126
23. Willerson J.T., and Ridker P.M. Inflammation as a cardiovascular risk factor. Circulation 109 Suppl II (2004) II-2-II-10
24. Ridker P.M., Rifai N., Rose L., Buring J.E., and Cook N.R. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of the first cardiovascular events. N Engl J Med 347 (2002) 1557-1565
25. Ridker P.M., Cannon C.P., Morrow D., Rifai N., Rose L.M., McCabe C.H., et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 352 (2005) 20-28
26. Nissen S.E., Tuzcu E.M., Schoenhagen P., Crowe T., Sasiela W.J., Tsai J., et al. Statin therapy, LDL cholesterol, C-reactive protein, and coronary disease. N Engl J Med 352 (2005) 29-38
27. Asanuma Y., Chung C.P., Oeser A., Shintani A., Stanley E., Raggi P., et al. Increased concentration of proatherogenic inflammatory cytokines in systemic lupus erythematosus: relationship to cardiovascular risk factors. J Rheumatol 33 (2006) 539-545
28. Maksimowicz-McKinnon K., Magder L.S., and Petri M. Predictors of carotid atherosclerosis in systemic lupus erythematosus. J Rheumatol 33 (2006) 2458-2463
29. Manger K., Kusus M., Forster C., Ropers D., Daniel W.G., Kalden J.R., et al. coronary artery calcification in young female patients with SLE. Ann Rheum Dis 62 (2003) 846-850
30. Borba E.F., and Bonfa E. Dyslipoproteinemias in systemic lupus erythematosus: influence of disease, activity, and anticardiolipin antibodies. Lupus 6 (1997) 533-539
31. Bruce I.N. Cardiovascular disease in lupus patients: should all patients be treated with statins and aspirin?. Best Pract Res Clin Rheumatol 19 (2005) 823-838
32. Borba E.F., Bonfa E., Vinagre C.G., Ramires J.A., and Maranhao R.C. Chylomicron metabolism is markedly altered in systemic lupus erythematosus. Arthritis Rheum 43 (2000) 1033-1040
33. Reichlin M., Fesmire J., Quintero-Del-Rio A.I., and Wolfson-Reichlin M. Autoantibodies to lipoprotein lipase and dyslipidemia in systemic lupus erythematosus. Arthritis Rheum 46 (2002) 2957-2963
34. de Carvalho J.F., Borba E.F., Viana V.S., Bueno C., Leon E.P., and Bonfa E. Anti-lipoprotein lipase antibodies: a new player in the complex atherosclerotic process in systemic lupus erythematosus?. Arthritis Rheum 50 (2004) 3610-3615
35. Borba E.F., Carvalho J.F., and Bonfa E. Mechanisms of dyslipoproteinemias in systemic lupus erythematosus. Clin Dev Immunol 13 (2006) 203-208
36. Delgado Alves J., Ames P.R., Donohue S., Stanyer L., Nourooz-Zadeh J., Ravirajan C., et al. Antibodies to high-density lipoprotein and beta2-glycoprotein I are inversely correlated with paraoxonase activity in systemic lupus erythematosus and primary antiphospholipid syndrome. Arthritis Rheum 46 (2002) 2686-2694
37. McMahon M., Grossman J., FitzGerald J., Dahlin-Lee E., Wallace D.J., Thong B.Y., et al. Proinflammatory high-density lipoprotein as a biomarker for atherosclerosis in patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum 54 (2006) 2541-2549
38. El Magadmi M., Ahmad Y., Turkie W., Yates A.P., Sheikh N., Bernstein R.M., et al. Hyperinsulinemia, insulin resistance, and circulating oxidized low density lipoprotein in women with systemic lupus erythematosus. J Rheumatol 33 (2006) 50-56
39. Chung C.P., Avalos I., Oeser A., Gebretsadik T., Shintani A., Raggi P., et al. High frequency of the metabolic syndrome in patients with systemic lupus erythematosus: association with disease characteristics and cardiovascular risk factors. Ann Rheum Dis (2006 Aug 10) [Epub ahead of print]
40. Sherer Y., and Shoenfeld Y. Mechanisms of disease: atherosclerosis in autoimmune diseases. Nat Clin Pract Rheumatol 2 (2006) 99-106
41. George J., Harats D., Gilburd B., Afek A., Levy Y., Schneiderman J., et al. Immunolocalization of beta2-glycoprotein I (apolipoprotein H) to human atherosclerotic plaques: potential implications for lesion progression. Circulation 99 (1999) 2227-2230
42. Petri M. The lupus anticoagulant is a risk factor for myocardial infarction (but not atherosclerosis): Hopkins Lupus Cohort. Thromb Res 114 (2004) 593-595
43. MacGregor A.J., Dhillon V.B., Binder A., Forte C.A., Knight B.C., Betteridge D.J., et al. Fasting lipids and anticardiolipin antibodies as risk factors for vascular disease in systemic lupus erythematosus. Ann Rheum Dis 51 (1992) 152-155
44. Doria A., Shoenfeld Y., Wu R., Gambari P.F., Puato M., Ghirardello A., et al. Risk factors for subclinical atherosclerosis in a prospective cohort of patients with systemic lupus erythematosus. Ann Rheum Dis 62 (2003) 1071-1077
45. Petri M., Lakatta C., Magder L., and Goldman D. Effect of prednisone and hydroxychloroquine on coronary artery disease risk factors in systemic lupus erythematosus: a longitudinal data analysis. Am J Med 96 (1994) 254-259
46. Tam L.S., Gladman D.D., Hallett D.C., Rahman P., and Urowitz M.B. Effect of antimalarial agents on the fasting lipid profile in systemic lupus erythematosus. J Rheumatol 27 (2000) 2142-2145
47. Rahman P., Gladman D.D., Urowitz M.B., Yuen K., Hallett D., and Bruce I.N. The cholesterol lowering effect of antimalarial drugs is enhanced in patients with lupus taking corticosteroid drugs. J Rheumatol 26 (1999) 325-330
48. Wallace D.J., Metzger A.L., Stecher V.J., Turnbull B.A., and Kern P.A. Cholesterol-lowering effect of hydroxychloroquine in patients with rheumatic disease: reversal of deleterious effects of steroids on lipids. Am J Med 89 (1990) 322
49. Borba E.F., and Bonfa E. Longterm beneficial effect of chloroquine diphosphate on lipoprotein profile in lupus patients with and without steroid therapy. J Rheumatol 28 (2001) 780-785
50. Isley W.L. Low-density lipoprotein cholesterol lowering in the prevention of CHD: How low should we go?. Curr Treat Options Cardiovasc Med 8 (2006) 289-297
51. Soubrier M., and Roux C. Statins in rheumatology. Joint Bone Spine 73 (2006) 159-168
52. Salmon JE. The Rheumatologist 2006;1:12-13.
53. Wajed J., Ahmad Y., Durrington P.N., and Bruce I.N. Prevention of cardiovascular disease in systemic lupus erythematosus-proposed guidelines for risk factor management. Rheumatology (Oxford) 43 (2004) 7-12
54. Urowitz M.B., Gladman D.D., Ibanez D., and Berliner Y. Modification of hypertension and hypercholesterolaemia in patients with systemic lupus erythematosus: a quality improvement study. Ann Rheum Dis 65 (2006) 115-117